SCHEMBL7606573

SCHEMBL7606573

CCCCn1c(=O)c2c(n(C)c1=O)N(OC=O)CN2C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 5/20 0.36
▸ PDE4A P27815 4/20 0.36
▸ PDE4B Q07343 4/20 0.36
▸ PDE4C Q08493 4/20 0.36
▸ PDE4D Q08499 4/20 0.36
▸ TNF P01375 2/20 0.36
▸ RGS4 P49798 3/20 0.32
▸ RGS8 P57771 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ ADORA2B P29275 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8004119 0.96 TNF (0.40) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL31337271 0.67 CYP1A2 (0.36) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL8666629 0.64 TNF (0.36) TNFADORA2BALDH1A1LMNA
SCHEMBL13223313 0.62 RGS4 (0.52) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL15745727 0.62 RGS4 (0.52) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL9162057 0.62 TNF (0.31) TNF
SCHEMBL31337358 0.61 CYP1A2 (0.36) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL838929 0.59 RGS4 (0.58) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL15946188 0.59 RGS4 (0.48) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL17394620 0.58 PDE4A (0.45) ADORA2APDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0719267-B1 SECOND MESSENGER CELL SIGNALING INHIBITORS CELL THERAPEUTICS INC (US) 2002-07-31 — — EP disclosed
US-6103730-A Amine substituted compounds CELL THERAPEUTICS, INC. (US) 2000-08-15 — — US disclosed
US-6100271-A Therapeutic compounds containing xanthinyl CELL THERAPEUTICS, INC. (US) 2000-08-08 — — US disclosed
US-6043250-A Methods for using therapeutic compounds containing xanthinyl CELL THERAPEUTICS, INC. (US) 2000-03-28 — — US disclosed
US-6020337-A Electronegative-substituted long chain xanthine compounds CELL THERAPEUTICS, INC. (US) 2000-02-01 — — US disclosed
CN-1040980-C Second messenger cell signaling inhibitors CELL THERAPEUTICS INC (US) 1998-12-02 — — CN disclosed
US-5824677-A SUBSTITUTED WITH HETEROCYCLIC RING, ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE CELL THERAPEUTICS, INC. (US) 1998-10-20 — — US disclosed
US-5807861-A Amine substituted xanthinyl compounds CELL THERAPEUTICS, INC. (US) 1998-09-15 — — US disclosed
US-5807862-A Therapeutic compounds containing pyrimidinyl moieties CELL THERAPEUTICS, INC. (US) 1998-09-15 — — US disclosed
US-5801182-A Amine substituted compounds CELL THERAPEUTICS, INC. (US) 1998-09-01 — — US disclosed
US-5777117-A ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE, CYTOTOXIC AGENTS; MICROBIOCIDES, FUNGICIDES CELL THERAPEUTICS, INC. (US) 1998-07-07 — — US disclosed
US-5750575-A ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANTS; CYTOTOXIC AGENTS; MICROBIOCIDES; FUNGICIDES CELL THERAPEUTICS, INC. (US) 1998-05-12 — — US disclosed
US-5641783-A ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS CELL THERAPEUTICS, INC. (US) 1997-06-24 — — US disclosed
EP-0719267-A1 SECOND MESSENGER CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 1996-07-03 — — EP disclosed
EP-0719267-A4 SECOND MESSENGER CELL SIGNALING INHIBITORS CELL THERAPEUTICS INC (US) 1996-02-16 — — EP disclosed
WO-1994022863-A1 SECOND MESSENGER CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 1994-10-13 — — WO disclosed
Send feedback